|
|
2009, the 2nd Annual China Biopharma Opportunities Summit concerns the latest biopharma and biologics innovations and industrialization issues. It provides an opportunity of multilateral and face-to-face interaction for biopharma community members - research institutes, biopharma corporations, and financial & investing institutions, etc. Upon the establishment and improvement of China Drug Supervision and Administration System, the global biopharma industry value chain has been shifting towards the biotech industry zones in China. From a global perspective, it is highly suggested that the issues on independent biopharma innovations and sustainable industrialization in China be further discussed and rationalized on such a platform. |
· The latest innovations on protein & gene pharmaceuticals, including humanized monoclonal antibody, protein biologics with genic recombinant technology, vaccine adjuvant for gene & polypeptide vaccine, large-scale mammalian cell cultivation technology, bioreactor technology and iRNA technology in tumor treatment, etc.
· Biopharma industry value chain management, including co- R&D effort around the globe, the upcoming industrialization model, industry expansion vs. capital expansion, and IP right protection, etc.
· In-depth review: the impact from bioinformatics, drug licensing and alliance management in China, and CRO market for diagnostic services.
· Generic pharma market trend in China: the expansion of domestic demand and venturing the oversea market.
· Showcase: biopharma technologies & intermediates, and laboratory technology, facilities, equipments and software support.
· Workshop: global attention on biochip
· Site Tour: face-to-face multilateral communication
|
|
|
